Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy
Only registered users can translate articles
Log In/Sign up
The link is saved to the clipboard
StatusCompleted
Sponsors
University of Oklahoma
CLINICAL TRIAL: NCT00929565
BioSeek: nct00929565
Keywords
Abstract
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.
The investigators plan to measure these factors prior to and after bronchoscopy.
Description
This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.
Dates
| Last Verified: | 03/31/2012 |
| First Submitted: | 06/23/2009 |
| Estimated Enrollment Submitted: | 06/24/2009 |
| First Posted: | 06/28/2009 |
| Last Update Submitted: | 04/04/2012 |
| Last Update Posted: | 04/08/2012 |
| Actual Study Start Date: | 05/31/2009 |
| Estimated Primary Completion Date: | 05/31/2010 |
| Estimated Study Completion Date: | 09/30/2011 |
Condition or disease
Hemoptysis
Phase
-
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Lung cancer Comparison between individuals with and without pulmonary malignancy |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Sampling method | Probability Sample |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Any patient scheduled to undergo bronchoscopy Exclusion Criteria: - Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000 - Patients not scheduled to undergo bronchoalveolar lavage (BAL) |
Outcome
Secondary Outcome Measures
1. Volume of blood loss during the procedure [1 day]
